North America Pharma Cloud Services Market by Application, Cloud Service, Cloud Type, and End User - Forecast to 2035 | AI and Hybrid Cloud Fuel 13.5% CAGR to $21.2 Billion
Dublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "North America Pharma Cloud Services Market by Area of Application, Type of Cloud Service, Type of Cloud, and End User - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering.
The North America pharma cloud services market is estimated to grow from USD 6.8 billion in the current year to USD 21.2 billion by 2035, representing a CAGR of 13.5% during the forecast period. Growth is being supported by pharmaceutical and biotechnology companies modernizing IT infrastructure across drug discovery, clinical development, manufacturing, regulatory compliance, and commercial operations.
Cloud computing has become a critical component of pharmaceutical digital transformation, providing scalable computing capacity, secure data storage, advanced analytics, and real-time collaboration. North America offers a favorable environment for adoption due to its mature healthcare IT ecosystem, established regulatory frameworks, and concentration of leading pharmaceutical, biotechnology, and cloud technology companies.
Cloud Adoption Accelerates Across the Pharmaceutical Lifecycle
Pharmaceutical organizations generate substantial volumes of genomic, clinical, imaging, real-world, and manufacturing data. As legacy on-premises infrastructure becomes less capable of supporting advanced research and operational requirements, companies are adopting cloud-based platforms to improve scalability, data access, workflow integration, and analytical performance.
In drug discovery, AI-enabled cloud platforms support target identification, molecular simulation, lead optimization, and candidate selection. Drug discovery currently represents the largest application segment and is projected to record the highest CAGR through 2035 as research teams increase their use of artificial intelligence, machine learning, and scalable computing resources.
Cloud adoption is also expanding throughout clinical development. Pharmaceutical sponsors, contract research organizations, investigators, and regulatory stakeholders are using cloud platforms for clinical trial management, decentralized and hybrid trials, pharmacovigilance, predictive analytics, regulatory submissions, and collaborative data review. The high level of clinical trial activity in North America, combined with rigorous compliance expectations, is strengthening demand for validated cloud infrastructure.
Within pharmaceutical manufacturing and supply chain management, cloud-based systems improve visibility across production, quality control, inventory movement, serialization, and supplier coordination. These capabilities are helping organizations strengthen operational resilience, improve product quality, and modernize complex global supply networks.
Key North America Pharma Cloud Services Market Growth Drivers
Enterprise collaborations demonstrate the increasing strategic importance of pharmaceutical cloud services. Merck's multi-year collaboration with Google Cloud, valued at up to USD 1 billion, includes plans to deploy an agentic AI platform across R&D, manufacturing, and commercial operations. AstraZeneca has also worked with AWS to develop an AI-powered assistant using Amazon Bedrock Agents. The platform has expanded to more than 1,000 users across clinical, regulatory, patient safety, and quality functions.
Market Challenges and Adoption Barriers
Despite strong growth prospects, migrating legacy on-premises systems containing decades of regulated data remains complex and resource-intensive. Pharmaceutical companies must manage validation, data integrity, business continuity, and organizational change without disrupting active research, clinical, or manufacturing programs.
Data privacy, cybersecurity, and cross-border governance are also significant considerations, particularly as companies adopt hybrid and multi-cloud models spanning multiple vendors and jurisdictions. Interoperability between cloud platforms, internal systems, and third-party networks continues to create integration challenges. Rapid advances in AI and cloud-native technologies further require organizations to reassess vendor capabilities, contractual terms, compliance requirements, and total cost of ownership.
Market Segment Insights
By Area of Application:
Drug discovery holds the largest market share and is expected to remain the fastest-growing application area through 2035. Demand is being driven by AI-enabled analytics and scalable infrastructure for processing complex scientific datasets and accelerating research decisions.
By Type of Cloud Service:
SaaS remains the preferred delivery model because it supports rapid implementation, continuous updates, and lower capital expenditure. Purpose-built platforms such as Veeva Vault Clinical are widely used to manage clinical trial data, sites, and study workflows.
By Type of Cloud:
Hybrid cloud accounts for the largest share of the North America pharma cloud services market. Its position reflects the need to combine the control and security of private infrastructure with the scalability and cost efficiency of public cloud resources.
By End User:
Pharmaceutical and life sciences companies represent the largest end-user segment and are expected to grow at a relatively higher CAGR. Organizations are replacing fragmented legacy systems with integrated cloud platforms that support faster innovation and enterprise-wide data access. Veeva Systems' expanded partnership with BioMarin Pharmaceutical illustrates this trend, with the collaboration broadening the use of cloud-based development and commercial platforms for rare disease drug development.
Competitive Landscape
The North America pharma cloud services provider landscape includes global technology companies, enterprise software vendors, consulting organizations, and specialized platform providers. Example market participants include:
Partnership activity remains strong, with platform utilization agreements representing a prominent deal category. These collaborations reflect demand for scalable, secure, and compliant infrastructure across the pharmaceutical lifecycle.
Report Coverage and Strategic Value
The report evaluates historical market trends since 2021 and provides forecasts through 2035 across application, cloud service, cloud type, and end-user segments. It assesses the provider landscape using factors such as company size, headquarters location, business model, quality certifications, application coverage, and additional capabilities.
Additional analysis includes provider benchmarking, company profiles, partnerships established since 2021, and potential cost savings across drug discovery, development, and manufacturing. The report also examines artificial intelligence, deep learning, machine learning, and quantum computing as enabling technologies, including their anticipated impact on cloud-related efficiencies and associated risks.
Insights were informed by discussions with stakeholders across the pharma cloud services value chain, including executives and specialists in growth, regulatory affairs, research services, life sciences, information and data management, AI consulting, strategic partnerships, and technical operations.
Outlook Through 2035
The North America pharma cloud services market is positioned for sustained expansion as pharmaceutical companies advance enterprise-wide digital transformation. AI integration, regulatory-grade infrastructure, decentralized clinical trials, and modernization of R&D and manufacturing workflows will remain central to market development. Cloud-enabled cost savings are expected to be especially significant in drug discovery and development, where scalable computing and advanced analytics can reduce experimentation cycles and improve time-to-market.
The report supports distributors, channel partners, market entrants, and business development teams by providing revenue forecasts, competitive intelligence, customer demand analysis, market barriers, and growth opportunities. It also includes a complementary PPT insights pack, Excel data packs for analytical modules, 15% free content customization, a detailed walkthrough with the research team, and a free updated report when the purchased edition is 6-12 months old or older.
Key Topics Covered:
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Cloud Computing
6.2.1. Types of Clouds and Cloud Services
6.2.2. Cloud Computing in Drug Discovery, Development and Manufacturing
6.2.3. Benefits and Limitations of Cloud Computing
6.3. Concluding Remarks
7. MARKET LANDSCAPE
7.1. Chapter Overview
7.2. North American Cloud Service Providers: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters (Region)
7.2.4. Analysis by Location of Headquarters (Country)
7.2.5. Analysis by Type of Company
7.2.6. Analysis by Cloud Service Business Model
7.2.7. Analysis by Quality Certifications
7.2.8. Analysis by Type of Cloud
7.2.9. Analysis by Type of Cloud Services
7.2.10. Analysis by Area of Application
7.2.11. Analysis by Additional Capabilities
7.2.12. Analysis by Additional Services Offered
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Overview of Peer Groups
8.5. Company Competitiveness Analysis
9. COMPANY PROFILES: PHARMA CLOUD SERVICE PROVIDERS
9.1. Chapter Overview
9.2. Microsoft
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Service Portfolio
9.2.4. Recent Developments and Future Outlook
9.3. Google
9.4. Amazon Web Services
9.5. IBM
9.6. Nutanix
9.7. Hewlett Packard Enterprise
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. North America Cloud Service Providers: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Focus Area
10.3.5. Most Active Players: Analysis by Number of Partnerships
10.3.6. Analysis by Geography
10.3.6.1. Local and International Agreements
10.3.6.2. Intracontinental and Intercontinental Agreements
11. COST SAVING ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.2.1. Overall Cost Saving Potential of Cloud-based Solutions for Drug Discovery, Development and Manufacturing, till 2035
11.3. Likely Cost Savings in Drug Discovery, till 2035
11.3.1. Likely Cost Savings in Drug Discovery in North America, till 2035
11.3.2. Likely Cost Savings in Drug Discovery in Europe, till 2035
11.3.3. Likely Cost Savings in Drug Discovery in Asia-Pacific, till 2035
11.3.4. Likely Cost Savings in Drug Discovery in Middle East and North Africa, till 2035
11.3.5. Likely Cost Savings in Drug Discovery in Latin America, till 2035
11.3.6. Likely Cost Savings in Drug Discovery in Rest of the World, till 2035
11.4. Likely Cost Savings in Drug Development, till 2035
11.4.1. Likely Cost Savings in Drug Development in North America, till 2035
11.4.2. Likely Cost Savings in Drug Development in Europe, till 2035
11.4.3. Likely Cost Savings in Drug Development in Asia-Pacific, till 2035
11.4.4. Likely Cost Savings in Drug Development in Middle East and North Africa, till 2035
11.4.5. Likely Cost Savings in Drug Development in Latin America, till 2035
11.4.6. Likely Cost Savings in Drug Development in Rest of the World, till 2035
11.5. Likely Cost Savings in Drug Manufacturing, till 2035
11.5.1. Likely Cost Savings in Drug Manufacturing in North America, till 2035
11.5.2. Likely Cost Savings in Drug Manufacturing in Europe, till 2035
11.5.3. Likely Cost Savings in Drug Manufacturing in Asia-Pacific, till 2035
11.5.4. Likely Cost Savings in Drug Manufacturing in Middle East and North Africa, till 2035
11.5.5. Likely Cost Savings in Drug Manufacturing in Latin America, till 2035
11.5.6. Likely Cost Savings in Drug Manufacturing in Rest of the World, till 2035
11.6. Concluding Remarks: Cost Saving Scenarios
12. ANTICIPATED TECHNOLOGY UPGRADES AFFILIATED OPPORTUNITIES
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Key Tools and Technologies
12.3.1. Artificial Intelligence
12.3.1.1. Artificial Intelligence in Pharmaceutical Product Development and Manufacturing
12.3.1.2. Likely Cost-Savings by Integrating Artificial Intelligence with Cloud Computing
12.3.2. Deep Learning
12.3.2.1. Deep Learning in Pharmaceutical Product Development and Manufacturing
12.3.2.2. Likely Cost-Savings by Integrating Deep Learning with Cloud Computing
12.3.3. Machine Learning
12.3.3.1. Machine Learning in Pharmaceutical Product Development and Manufacturing
12.3.3.2. Likely Cost-Savings by Integrating Machine Learning with Cloud Computing
12.3.4. Quantum Computing
12.3.4.1. Quantum Computing in Pharmaceutical Product Development and Manufacturing
12.3.4.2. Likely Cost-Savings by Integrating Quantum Computing with Cloud Computing
12.4. Extent of Innovation versus Associated Risk Analysis
12.4.1. Results and Discussion
13. MARKET IMPACT ANALYSIS
13.1. Chapter Overview
13.2. Market Drivers
13.3. Market Restraints
13.4. Market Opportunities
13.5. Market Challenges
13.6. Conclusion
14. NORTH AMERICA PHARMA CLOUD SERVICES MARKET
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. North America Pharma Cloud Services Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
14.3.1. Roots Analysis Perspective on Market Growth
14.3.2. Scenario Analysis
14.3.2.1. Conservative Scenario
14.3.2.2. Optimistic Scenario
14.4. Key Market Segmentations
15. NORTH AMERICA PHARMA CLOUD SERVICES MARKET, BY AREA OF APPLICATION
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. North America Pharma Cloud Services Market: Distribution by Area of Application
15.3.1. North America Pharma Cloud Services Market for Drug Discovery, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
15.3.2. North America Pharma Cloud Services Market for Drug Development, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
15.3.3. North America Pharma Cloud Services Market for Drug Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
15.4. Data Triangulation and Validation
16. NORTH AMERICA PHARMA CLOUD SERVICES MARKET, BY TYPE OF CLOUD SERVICE
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. North America Pharma Cloud Services Market: Distribution by Type of Cloud Service
16.3.1. North America Pharma Cloud Services Market for Software as a Service (SaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
16.3.2. North America Pharma Cloud Services Market for Infrastructure as a Service (IaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
16.3.3. North America Pharma Cloud Services Market for Platform as a Service (PaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
16.3.4. North America Pharma Cloud Services Market for Others, Historical Trends (since 2021) and Forecasted Estimate, (till 2035)
16.4. Data Triangulation and Validation
17. NORTH AMERICA PHARMA CLOUD SERVICES MARKET, BY TYPE OF CLOUD
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. North America Pharma Cloud Services Market: Distribution by Type of Cloud
17.3.1. North America Pharma Cloud Services Market for Hybrid Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
17.3.2. North America Pharma Cloud Services Market for Public Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
17.3.3. North America Pharma Cloud Services Market for Private Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
17.4. Data Triangulation and Validation
18. NORTH AMERICA PHARMA CLOUD SERVICES MARKET, BY END USER
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. North America Pharma Cloud Services Market: Distribution by End User
18.3.1. North America Pharma Cloud Services Market for Pharmaceutical and Life Sciences Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
18.3.2. North America Pharma Cloud Services Market for CROs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
18.3.3. North America Pharma Cloud Services Market for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
18.4. Data Triangulation and Validation
19. CONCLUDING REMARKS
21. APPENDIX I: TABULATED DATA
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/57m223
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.